Symadex is currently in a Phase 2 study for women with metastatic breast cancer, and has the potential to be active in hematological malignancies. Xanthus is also exploring the use of Symadex and follow-on compounds for the treatment of a number of autoimmune diseases, such as multiple sclerosis and inflammatory bowel disease. Early preclinical data has shown encouraging signs of activity in models of autoimmune disease. Given the compound's safety profile and oral availability, Xanthus believes Symadex™ represents the potential for a large-scale drug opportunity. Further preclinical studies are currently being conducted, after which the Company expects to enter clinical development.
http://www.xanthus.com/products_symadex.htm

glaxosmithkline says neuroscience pipeline spans 13 different ...
CNNMoney.com - USA
Compounds being developed for the treatment of multiple sclerosis (MS), ofatamumab and firategrast, will move into Phase II testing early in 2008. ...Compounds being developed for the treatment of multiple sclerosis (MS), ofatamumab and firategrast, will move into Phase II testing early in 2008.

See all stories on this topic

Innovative Research Advances Stem Cell and Bone Marrow Transplantation
PharmaLive.com (press release) - Newtown,PA,USA
Stem cells are the body's "parent" cells and can produce specialized cells that differentiate and become various tissues in the body, such as those found in ...
See all stories on this topic

Innovative Research Advances Stem Cell and Bone Marrow Transplantation
PR Newswire (press release) - New York,NY,USA
Production of specialized stem cells increases when new compound is added to standard pre-transplantation routine for multiple myeloma patients [Abstract ...
See all stories on this topic

Biogen Idec, Remaining Independent, Loses $6 Billion in Value
Bloomberg - USA
Biogen researchers believe the compound, BG-12, works by damping down inflammation, while also protecting healthy cells. It would be used for relapsing, ...
See all stories on this topic

Analyst Actions: Biogen Idec, Washington Mutual, Rigel, Plantronics
BusinessWeek - USA
... bent towards Rituxan in Lupus, but this is balanced by emerging competitive CD20 landscape, including DNA's second generation anti-CD20, ocrelizumab. ...
See all stories on this topic

Blog to reveal teen's battle with MS
ChronicleLive - Newcastle upon Tyne,England,UK
And at 14, the pupil at Gateshead's Thomas Hepburn School is the only person under 18 to try out the MS wonder drug Campath. Patsy is campaigning to win ...
See all stories on this topic

Taking antibiotic with interferon could help MS patients: study
CBC.ca - Alberta, Canada
Taking a common antibiotic along with standard interferon treatment may be effective in helping some people with multiple sclerosis, a small preliminary ...
See all stories on this topic

Treatment Prospects For Multiple Sclerosis Will Improve, UK The next 10 years should see further improvement in treatment prospects for people with multiple sclerosis, according to a report published by the Association of the British Pharmaceutical Industry (ABPI).	13 Dec 2007
New Research Reveals People With Neurological Conditions Are Being Left In An Information Void And Not Receiving Adequate Care, UK According to new research revealed the great majority (82%) of the 10 million people with neurological conditions in the UK1,2 such as multiple sclerosis and Parkinson's disease do not have as much information as they want about their condition.	13 Dec 2007
Xanthus' Symadex Demonstrates Ability To Increase Spinal Cord Remyelination In Multiple Sclerosis Model Xanthus Pharmaceuticals, Inc. presented preclinical data further supporting the potential for Symadex™ to reverse the clinical and pathological signs of multiple sclerosis (MS), including new data demonstrating increased spinal cord remyelination.	13 Dec 2007

Biogen Idec gives up on sale; shares plummet
Bizjournals.com - Charlotte,NC,USA
Biogen split revenue with Ireland's Elan Corp. on sales of multiple sclerosis drug Tysabri and with Genentech on sales of cancer treatment Rituxan. ...
See all stories on this topic

Biogen Fails To Attract Bids; Firm To Operate Independently
BioWorld Online - Atlanta,GA,USA
The fda's delay in reviewing Tysabri in Crohn's disease in order to examine the drug's risk management program, followed by Biogen's lower-than-expected ...
See all stories on this topic

Credit Suisse Upgrades Biogen Idec (BIIB) to Neutral
StreetInsider.com (subscription) - Birmingham,MI,USA
The firm says the focus in 2008 is on the growth of Tysabri, Rituxan growth/challenges, and a positive outlook from the co's pipeline. ...
See all stories on this topic

Biogen retreats
Financial Times - London,England,UK
A deal at anywhere near that price might have been misguided – it would have required a prematurely bullish bet on Tysabri, the multiple sclerosis drug ...
See all stories on this topic

Biogen Idec is no longer for sale
Boston Globe - United States
The future is uncertain for Biogen Idec's other major drug, Tysabri - another MS treatment - as well as its pipeline of experimental drugs. ...
See all stories on this topic

BIOTECH STOCKS Biogen, Neurocrine lead benchmark indexes lower
MarketWatch - USA
One of Biogen's key growth drivers, the multiple sclerosis medication, Tysabri, is marketed with Irish drugmaker Elan Corp. Biogen said the two companies ...
See all stories on this topic